Table 3.

Univariable survival analyses of breast cancer-specific survival and overall survival

	Breast cancer-specific survival				Overall survival
Factor	Event/at risk	HR	95% CI	P	Event/at risk	HR	95% CI	P
Tumor size
pT1	7/44	1			11/44	1
pT2	9/42	1.47	0.55–3.96	0.439	16/42	1.70	0.79–3.67	0.169
Node status
pN0	4/33	1			9/33	1
pN+	12/52	2.00	0.64 –6.19	0.222	18/52	1.33	0.60–2.96	0.484
Histological grade
1	3/16	1			6/16	1
2	10/57	0.94	0.26–3.42	0.924	16/57	0.76	0.30–1.94	0.564
3	3/11	1.48	0.30–7.35	0.631	5/11	1.30	0.40–4.28	0.661
Histological grade
1 + 2	13/73	1			22/73	1
3	3/11	1.56	0.44–5.46	0.335	5/11	1.61	0.61–4.25	0.335
Age
< 55 years	7/35	1			7/35	1
≥ 55 years	9/51	0.93	0.35–2.51	0.890	20/51	2.09	0.89–4.95	0.085
ER
≥ 10%	15/75	1			26/75	1
< 10%	1/7	0.63	0.08–4.73	0.646	1/7	0.36	0.05–2.65	0.294
PR
≥ 10%	11/55	1			17/55	1
< 10%	4/27	0.72	0.23–2.25	0.566	9/27	0.98	0.43–2.19	0.951
Chemotherapy*
Yes	6/30	1			6/30	1
No	10/56	0.93	0.34–2.57	0.893	21/56	1.97	0.80–4.89	0.135
AAS
> 16.7	13/79	1			21/79	1
≤ 16.7	3/7	3.81	1.07–13.56	0.026	6/7	5.37	2.14–13.51	< 0.001
Z-4OHtam
> 3.26 nM	12/76	1			20/76	1
≤ 3.26 nM	4/10	3.56	1.14–11.11	0.020	7/10	4.05	1.70–9.64	0.001
Z-endoxifen
> 9.00 nM	13/79	1			22/79	1
≤ 9.00 nM	3/7	3.73	1.05–13.23	0.029	5/7	4.03	1.51–10.74	0.003

* Did the patients receive chemotherapy according to the treatment guidelines at the time

AAS antiestrogenic activity score, CI confidence interval, ER estrogen receptor, HR hazard ratio, pN pathologic node status, PR progesterone receptor, pT pathologic tumor size